Last 32 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.34 | 5.42 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 3.71 | — | 1.67 | 2.67 | 13.27 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -72.1% | — | — | — | — | |
| P/S Ratio | 26.00 | 1.80 | — | 3.28 | 826.35 | 143.69 | 73.45 | 20.29 | 107.51 | 98.58 | 6.08 | 20.17 | 119.20 | 216.52 | 12.34 | 17.05 | 1.74 | — | 0.70 | 1.72 | 14.06 |
| — | -98.7% | — | -83.9% | +668.6% | +45.8% | +1108.6% | +0.6% | -9.8% | -54.5% | -50.8% | +18.3% | +6763.4% | — | +1658.2% | +888.9% | -87.6% | — | -100.0% | -99.9% | -99.8% | |
| P/B Ratio | 1.91 | 1.75 | 1.62 | 1.10 | 1.00 | 0.74 | 0.85 | 0.87 | 0.82 | 0.85 | 0.89 | 0.85 | 0.75 | 1.82 | 1.58 | 1.62 | 1.21 | 1.73 | 1.73 | 3.91 | 6.65 |
| — | +137.8% | +90.4% | +25.7% | +20.8% | -12.9% | -3.6% | +2.5% | +9.8% | -53.4% | -43.8% | -47.5% | -37.9% | +5.1% | -8.8% | -58.6% | -81.8% | -79.9% | -82.8% | -17.7% | +25.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 37.40 | 6.58 | 0.90 | 1.62 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -92.2% | — | — | — | |
| EV / EBITDA | — | 5.03 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.25 | — | 0.69 | 2.35 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 5.07 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.27 | — | 0.69 | 2.21 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.9% | 100.0% | 9793.1% | 672.1% | -63005.0% | -7932.9% | -3779.1% | -617.5% | -8102.9% | -3320.0% | -74.8% | -533.6% | -5397.0% | -4327.3% | -153.4% | -226.2% | 63.6% | 452.0% | 85.4% | 77.2% | -2.8% |
| — | +101.3% | +359.1% | +208.8% | -677.6% | -138.9% | -4953.7% | -15.7% | -50.1% | +23.3% | +51.3% | -135.9% | -8588.7% | -1057.4% | -279.7% | -392.9% | +2380.3% | +791.2% | -14.6% | -22.8% | -102.8% | |
| Operating Margin | -682.7% | 30.7% | 459241.4% | -57.1% | -72267.9% | -9754.3% | -4602.5% | -946.7% | -9718.7% | -5158.7% | -142.0% | -828.1% | -7075.9% | -5667.3% | -227.7% | -304.6% | 52.1% | 554.3% | 82.3% | 70.3% | -51.5% |
| — | +100.3% | +10078.1% | +94.0% | -643.6% | -89.1% | -3140.1% | -14.3% | -37.3% | +9.0% | +37.6% | -171.9% | -13693.9% | -1122.3% | -376.8% | -533.0% | +201.0% | +1508.7% | +100.3% | +100.2% | +99.9% | |
| Net Margin | -638.9% | 33.5% | 433431.0% | -67.0% | -67975.4% | -9139.9% | -3989.6% | -845.2% | -8979.7% | -4500.1% | -115.8% | -690.9% | -6192.2% | -5129.7% | -223.8% | -205.6% | 46.8% | 188.3% | 42.1% | 64.6% | 106.6% |
| — | +100.4% | +10964.0% | +92.1% | -657.0% | -103.1% | -3345.6% | -22.3% | -45.0% | +12.3% | +48.3% | -236.0% | -13329.8% | -2824.6% | -631.8% | -418.2% | -56.1% | +439.3% | +100.2% | +100.2% | +100.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -45.7% | 8.9% | -15.9% | -5.5% | -18.7% | -11.1% | -11.0% | -8.7% | -16.0% | -9.3% | -4.2% | -7.1% | -9.4% | -10.3% | -7.0% | -4.8% | 8.5% | -3.9% | 30.2% | 45.5% | 13.7% |
| — | +180.1% | -44.5% | +37.2% | -17.1% | -20.0% | -165.0% | -23.2% | -70.4% | +9.9% | +40.2% | -47.8% | -209.7% | -166.2% | -123.0% | -110.6% | -37.5% | -143.5% | +222.3% | +429.4% | +211.3% | |
| ROA | -36.5% | 7.1% | -12.4% | -4.2% | -14.8% | -8.9% | -8.9% | -7.2% | -13.5% | -8.0% | -3.5% | -5.9% | -7.6% | -7.9% | -5.2% | -3.7% | 6.6% | -2.8% | 21.4% | 33.2% | 9.7% |
| — | +180.5% | -38.6% | +41.2% | -9.3% | -11.1% | -154.2% | -23.4% | -77.1% | -0.7% | +31.8% | -58.3% | -215.5% | -185.6% | -124.1% | -111.1% | -32.3% | -149.3% | +230.3% | +392.5% | +193.0% | |
| ROIC | -40.3% | 7.7% | -14.8% | -3.8% | -16.6% | -10.4% | -11.1% | -7.9% | -14.2% | -8.6% | -4.0% | -7.4% | -10.7% | -12.7% | -8.2% | -8.4% | 15.4% | -17.7% | 59.7% | 58.9% | -26.5% |
| — | +174.0% | -33.7% | +52.2% | -16.8% | -20.8% | -174.6% | -7.7% | -33.5% | +31.9% | +50.7% | +12.5% | -169.3% | +28.5% | -113.7% | -114.3% | +158.1% | -151.8% | +238.1% | +359.5% | -15.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.09 | 0.12 | 0.24 | 0.13 | 0.11 | 0.09 | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.06 | 0.06 | 0.07 | 0.07 | 0.10 | 0.08 |
| — | -12.0% | +27.7% | +187.0% | +38.4% | +35.1% | +17.6% | +8.7% | +19.3% | +10.1% | +19.8% | +27.2% | +25.0% | +5.5% | -4.5% | -35.9% | -26.0% | -30.0% | -36.6% | -1.9% | +323.3% | |
| Debt / EBITDA | — | 1.22 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.67 | — | 0.13 | 0.24 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.54 | 6.04 | 7.11 | 5.54 | 7.25 | 7.01 | 6.79 | 8.71 | 8.94 | 12.51 | 12.90 | 9.05 | 10.72 | 8.63 | 4.86 | 4.93 | 7.83 | 4.79 | 3.66 | 4.58 | 4.56 |
| — | -13.8% | +4.7% | -36.4% | -18.8% | -44.0% | -47.3% | -3.8% | -16.6% | +45.0% | +165.3% | +83.7% | +36.9% | +80.2% | +33.0% | +7.6% | +71.6% | -18.9% | +32.9% | -41.3% | -58.7% | |
| Quick Ratio | 5.54 | 6.04 | 7.11 | 5.54 | 7.25 | 7.01 | 6.79 | 8.71 | 8.94 | 12.51 | 12.90 | 9.05 | 10.72 | 8.63 | 4.86 | 4.93 | 7.83 | 4.79 | 3.66 | 4.58 | 4.56 |
| — | -13.8% | +4.7% | -36.4% | -18.8% | -44.0% | -47.3% | -3.8% | -16.6% | +45.0% | +165.3% | +83.7% | +36.9% | +80.2% | +33.0% | +7.6% | +71.6% | -18.9% | +32.9% | -41.3% | -58.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 32 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying VIR stock.
Vir Biotechnology, Inc.'s current P/E is -3.3x. The average P/E over the last 1 quarters is 5.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Vir Biotechnology, Inc.'s current operating margin is -682.7%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Vir Biotechnology, Inc.'s business trajectory between earnings reports.